Targeting PD-1/PD-L1 interactions for cancer immunotherapy.

31 Indeed, there was a highly significant concordance between membranous expression of PD-L1 by naevi and in situ or advanced melanoma (35–39% exhibit a > 5% positivity using the 5H1 Ab) with the presence of CD3 + and CD8 + immune infiltrates (TILs). 31 Interferon type II was detectable by qRT-PCR assessed after laser capture microdissection of the interface between TILs and PD-L1 expression by tumor cells.

also in 132,142 other papers